drugset / Trial / NCT01064947

Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis

NCT01064947

Phase 4 Completed 29 enrolled Derm Research, PLLC GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

Skin infections may complicate the treatment of atopic dermatitis.The use of topical ointments has become very important to avoid the use of oral antibiotics. There is little supporting literature regarding the use of topical antibiotics in secondarily infected atopic dermatitis. This study will investigate the safety and effectiveness of Altabax ointment use in treating secondarily infected atopic dermatitis caused by Staphylococcus aureus and Streptococcus pyogenes.

Timeline

Start
2010-02
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Retapamulin Small molecule 1 % Topical